Drews, Ruben M. http://orcid.org/0000-0001-7360-4970
Hernando, Barbara
Tarabichi, Maxime
Haase, Kerstin http://orcid.org/0000-0002-0944-5618
Lesluyes, Tom http://orcid.org/0000-0003-2251-5884
Smith, Philip S. http://orcid.org/0000-0002-9306-1747
Morrill Gavarró, Lena http://orcid.org/0000-0002-2242-4010
Couturier, Dominique-Laurent http://orcid.org/0000-0001-5774-5036
Liu, Lydia http://orcid.org/0000-0001-6026-3169
Schneider, Michael
Brenton, James D. http://orcid.org/0000-0002-5738-6683
Van Loo, Peter http://orcid.org/0000-0003-0292-1949
Macintyre, Geoff http://orcid.org/0000-0003-3906-467X
Markowetz, Florian http://orcid.org/0000-0002-2784-5308
Article History
Received: 31 July 2020
Accepted: 21 April 2022
First Online: 15 June 2022
Competing interests
: J.D.B., G.M., F.M. are co-founders, directors and share holders of Tailor Bio Ltd. Cancer Research UK, the University of Cambridge and the Spanish National Cancer Research Centre (CNIO) are in the process of applying for a patent application GB2114203.9 covering the copy number signature methodology and drug target associations that lists R.M.D., B.H., G.M. and F.M. as inventors. G.M., F.M. and J.D.B are listed on a patent on using copy number signatures to predict response to doxorubicin treatment in ovarian cancer (PCT/EP2021/065058).